FDA
approval
· 2016-12-16
FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
Summary
FDA approved a supplemental application for Actavis Pharma to manufacture and distribute a generic buprenorphine and naloxone product for opioid use disorder.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)